Long noncoding RNA NEAT1 regulate papillary thyroid cancer progression by modulating miR-129-5p/KLK7 expression

Area of Science:

• Molecular Oncology
• Cancer Biology
• Genetics

Background:

• Papillary thyroid cancer (PTC) presents treatment challenges.
• Identifying novel molecular targets is crucial for effective PTC therapy.

Purpose of the Study:

• To investigate the lncRNA-NEAT1/miR-129-5p/KLK7 interaction in papillary thyroid cancer.
• To explore the therapeutic potential of targeting this pathway for PTC treatment.

Main Methods:

• Microarray analysis and R language for lncRNA/miRNA selection.
• Luciferase reporter and RNA pull-down assays for target validation.
• In vitro (proliferation, apoptosis, invasion, migration) and in vivo assays to assess functional effects.
• Western blot and qRT-PCR for expression analysis.

Main Results:

• Long non-coding RNA NEAT1 (lncRNA NEAT1) is upregulated in PTC and promotes proliferation, invasion, and migration while reducing apoptosis.
• lncRNA NEAT1 and miR-129-5p negatively correlate and their combined action suppresses PTC progression.
• miR-129-5p directly targets and downregulates KLK7, a protein that accelerates PTC deterioration.
• Silencing lncRNA NEAT1 inhibits tumor growth in vitro and in vivo.

Conclusions:

• lncRNA NEAT1 suppression is a potential therapeutic strategy for PTC.
• Upregulating miR-129-5p and subsequently suppressing KLK7 expression are key mechanisms involved.
• The lncRNA-NEAT1/miR-129-5p/KLK7 axis represents a promising therapeutic target for papillary thyroid cancer.